Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation
ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

2025.07.09

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint
A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

2025.05.31

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma
ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025
Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation
CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

2025.03.11

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com